MARKET

SRDX

SRDX

Surmodics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

40.62
+1.84
+4.74%
Opening 15:46 12/04 EST
OPEN
38.71
PREV CLOSE
38.78
HIGH
40.71
LOW
38.71
VOLUME
15.73K
TURNOVER
--
52 WEEK HIGH
49.00
52 WEEK LOW
22.06
MARKET CAP
554.47M
P/E (TTM)
511.59
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Why Is SurModics (SRDX) Up 6.4% Since Last Earnings Report?
Zacks · 4h ago
6-Month Data From the Surmodics Avess AV Fistula DCB First-in-Human Study Presented at VIVA 2020
Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020; Study finds 100 percent target lesion patency at 30 days.
Business Wire · 11/09 13:05
6-Month Data From the Surmodics Avess(TM) AV Fistula DCB First-in-Human Study Presented at VIVA 2020
Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS first-in-human (FIH) study of the company's Avess(TM) AV Fistula drug-coated balloon (DCB) was shared during a morning session at the Vascular Interventional Advances (VIVA) 2020 virtual conference.
BusinessWire · 11/09 10:05
Surmodics (SRDX) Reports Q4 Loss, Revenues Beat Estimates
Surmodics (SRDX) registered revenue decline in each of its core units in the fourth quarter.
Zacks · 11/05 14:13
Surmodics EPS misses by $0.10, beats on revenue
Surmodics (SRDX): Q4 Non-GAAP EPS of -$0.18 misses by $0.10; GAAP EPS of -$0.22 misses by $0.06.Revenue of $22.5M (-27.0% Y/Y) beats by $1.73M.FY21 guidance: Due to the continued uncertainty
Seekingalpha · 11/04 22:13
Surmodics Reports Fourth Quarter Fiscal 2020 Results
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 fourth quarter ended September 30, 2020.
BusinessWire · 11/04 18:05
Surmodics to Webcast Fourth Quarter Fiscal 2020 Earnings Conference Call on November 4
Surmodics, Inc. (Nasdaq: SRDX), to webcast Fourth quarter fiscal 2020 earnings in a conference call on November 4, 2020.
Business Wire · 10/27 12:30
Surmodics to Webcast Fourth Quarter Fiscal 2020 Earnings Conference Call on November 4
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter fiscal 2020 conference call on Wednesday, November 4, at 4 p.m. CT (5 p.m. ET). The Company will issue an earnings news release after the market closes that afternoon.
BusinessWire · 10/27 09:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SRDX. Analyze the recent business situations of Surmodics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SRDX stock price target is 64.25 with a high estimate of 76.00 and a low estimate of 57.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 12.55M
% Owned: 91.94%
Shares Outstanding: 13.65M
TypeInstitutionsShares
Increased
40
262.60K
New
26
99.98K
Decreased
55
378.30K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.46%
Healthcare Equipment & Supplies
+1.20%
Key Executives
Non-Executive Chairman/Independent Director
Susan Knight
Chief Executive Officer/President/Director
Gary Maharaj
Chief Financial Officer/Vice President - Finance
Timothy Arens
Chief Operating Officer
Thomas Greaney
Senior Vice President/Chief Marketing Officer
Teri Sides
Senior Vice President/General Counsel/Secretary
Gordon Weber
Senior Vice President
Charles Olson
Vice President/General Manager
Joseph Stich
Vice President
Nusrath Sultana
Vice President - Research & Development
Gregg Sutton
Independent Director
Jose Bedoya
Independent Director
David Dantzker
Independent Director
Lisa Heine
Independent Director
Ronald Kalich
Independent Director
Shawn McCormick
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About SRDX
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company's Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company's In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of SurModics, Inc. stock information, including NASDAQ:SRDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRDX stock methods without spending real money on the virtual paper trading platform.